| Today’s Big NewsSep 18, 2023 |
| By Gabrielle Masson GSK’s Senior Vice President and Head of Research John Lepore, M.D., has left the company at the same time the U.K. pharma undergoes a slight shuffling of its R&D operations. |
|
|
|
| Virtual Event |  |
|
|
By Angus Liu Alnylam and BridgeBio are each on track to enter the blockbuster transthyretin amyloidosis cardiomyopathy (ATTR-CM) market. But doctors say they'll mostly stick with Pfizer's first-to-market offerings. |
By Andrea Park One of GE HealthCare’s first moves after spinning out from under the General Electric umbrella earlier this year was to acquire Caption Health, and the buyout is already paying off. |
By Kevin Dunleavy Already approved as an injection to reduce wrinkles in the forehead and around the eyes, AbbVie's Botox is in position to expand its cosmetic uses to the moderate to severe form of platysma prominence, a condition which causes muscle bands to protrude from the neck. Two phase 3 trials have proven the injected treatment can resolve the protrusions. |
|
October 16-18, 2023 | Boston, MA Brought to you by the editors behind Fierce Biotech, this conference is a unique venue where biotech executives can network and learn how to improve their partnership and pipeline strategies. It’s the only event that covers the entire pharma R&D spectrum, from basic research through clinical trials. Countdown is on! Register today to save $200 
|
|
By Max Bayer BioNTech has partnered up with pandemic prevention organization CEPI to the tune of $90 million to help advance a couple of phase 1 stage mpox vaccines. The funding is part of CEPI's latest 100 Days Mission to help stymie future outbreaks. |
By Conor Hale The observational study showed that Jada was able to rapidly control postpartum hemorrhage—a major cause of maternal morbidity in the U.S.—including in women who had a vaginal delivery as well as those who underwent a C-section. |
By Nick Paul Taylor Blackstone Life Sciences’ $250 million bet on an ex-Novartis drug candidate has racked up another phase 2 win. The data show Anthos Therapeutics’ abelacimab significantly cut bleeding compared to Bayer and Johnson & Johnson’s Xarelto, adding to evidence it can treat thrombosis without affecting hemostasis. |
By Angus Liu,Kevin Dunleavy,Eric Sagonowsky In this tracker, Fierce Pharma is recording the regulatory progress of in-market products, including expansions into key geographies and new indications. Some of these updates may not meet the bar for standalone stories, but we think they are still worth mentioning. |
By Max Bayer Lyndra Therapeutics is laying off staff two months after a CEO swap and as interim data from a pivotal trial for a schizophrenia drug nears. The company's lead asset is a long-acting, oral version of Johnson & Johnson's Uzedy. |
By Andrea Park The DOT device measures only about one centimeter across. It doesn’t connect to any leads nor does it contain a battery. |
By Gabrielle Masson Acepodia has snagged Nobel laureate Carolyn Bertozzi, Ph.D., to serve as chief scientific adviser as the biotech works to transform the cell therapy space for patients with solid tumors and hematologic cancers. |
Fierce podcasts Don’t miss an episode |
| This week on "The Top Line," we discuss the trends seen at Cannes Lions, the top compensated CEOs in the industry, and the cancer drug shortage |
|
|---|
|
|
|
Tuesday, September 26, 2023 | 11am ET / 8am PT This webinar will focus on the latest advancements in bioprocessing for cell and gene therapies (CGTs), including the improved consistency and reduced production costs associated with closed manufacturing. Register now. 
|
|
eBook Emulate in vivo biology with next-generation in vitro technology. Sponsored by: Emulate |
Whitepaper Learn more about how you can improve the productivity of your research and manufacturing operations and accelerate the journey from laboratory to saving lives. Sponsored by: JLL |
Whitepaper Learn how outsourcing the buffer preparation can reallocate resources to support core activities of your bioprocess production. Sponsored by: Thermo Fisher Scientific |
Whitepaper From trial site feasibility and patient populations to data analysis, generative AI has the potential to revolutionize drug discovery and clinical trial recruitment at both the therapeutic area and indication level. Sponsored by: H1 |
Whitepaper Learn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
Whitepaper By 2030, the global demand for biologics is projected to grow at a CAGR of 8.7% and the challenges, risks, and costs of bringing large molecule products to market are growing exponentially. Sponsored by: ThermoFisher Scientific |
Whitepaper 15 biotech executives from the Cambridge area discuss the current biotech landscape, as well as challenges, opportunities, and best practices for emerging biotech companies seeking success in the UK and beyond. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| |
|
